Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa

NCT07482813 is registered in ClinicalTrials.gov with Paradigm Therapeutics as lead sponsor.

NCT NCT07482813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07482813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa
Lead sponsor
Paradigm Therapeutics
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
October 19, 2027
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa (eb)